155 related articles for article (PubMed ID: 35484313)
41. Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
Stathopoulos GP; Ardavanis A; Papakotoulas P; Pectasides D; Papadopoulos G; Antoniou D; Athanasiadis A; Trafalis D; Anagnostopoulos A; Koutantos J; Vaslamatzis M
Anticancer Drugs; 2010 Feb; 21(2):202-5. PubMed ID: 20010424
[TBL] [Abstract][Full Text] [Related]
42. Does granulocyte colony-stimulating factor affect survival in patients with advanced non-small cell lung cancer?
Kasymjanova G; Kreisman H; Correa JA; Dajczman E; Small D
J Thorac Oncol; 2006 Jul; 1(6):564-70. PubMed ID: 17409918
[TBL] [Abstract][Full Text] [Related]
43. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
Krzemieniecki K; Sevelda P; Erdkamp F; Smakal M; Schwenkglenks M; Puertas J; Trojan A; Szabo Z; Bendall K; Maenpaa J
Support Care Cancer; 2014 Mar; 22(3):667-77. PubMed ID: 24154740
[TBL] [Abstract][Full Text] [Related]
44. The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
Saijo N; Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y
Semin Oncol; 1994 Feb; 21(1 Suppl 1):54-8. PubMed ID: 7512277
[No Abstract] [Full Text] [Related]
45. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
46. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
47. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
48. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
49. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
50. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
51. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
52. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
[TBL] [Abstract][Full Text] [Related]
53. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
[TBL] [Abstract][Full Text] [Related]
54. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.
Haim N; Shulman K; Goldberg H; Tsalic M
Med Oncol; 2005; 22(3):229-32. PubMed ID: 16110133
[TBL] [Abstract][Full Text] [Related]
55. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
56. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
57. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
Shi YK; Feng FY; Sun Y
Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
[TBL] [Abstract][Full Text] [Related]
58. A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
Philip PA; Rea D; Mitchell K; Carmichael J; Harris AL; Talbot DC
Clin Oncol (R Coll Radiol); 1999; 11(2):84-9. PubMed ID: 10378632
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
[TBL] [Abstract][Full Text] [Related]
60. Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute.
Goodman LM; Moeller MB; Azzouqa AG; Guthrie AE; Dalby CK; Earl MA; Cheng C; Pennell NA; Shapiro M; Velcheti V; Stevenson JP
J Oncol Pract; 2016 Jan; 12(1):e101-7. PubMed ID: 26759474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]